Icahn Enterprises IEP Pharma — Partners Capital
Other segment segments
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:PartnersCapital.
The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Icahn Enterprises's pharma — partners capital.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Icahn Enterprises's pharma — partners capital?
- Icahn Enterprises (IEP) reported pharma — partners capital of $161M in Q1 2026.
- How has Icahn Enterprises's pharma — partners capital changed year-over-year?
- Icahn Enterprises's pharma — partners capital decreased by 25.1% year-over-year, from $215M to $161M.
- What is the long-term trend for Icahn Enterprises's pharma — partners capital?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — partners capital has grown at a -7.8% compound annual growth rate (CAGR), from $1.06B to $764M.
- What does pharma — partners capital mean?
- Represents the equity interest held by partners or parent entities within the pharmaceutical segment. This metric indicates the net investment value attributable to the primary stakeholders after accounting for all liabilities. It is essential for understanding the ownership structure and equity base of the business unit.